| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 04/24/2003 | US20030078258 Adrenergic blocking agents |
| 04/24/2003 | US20030078254 Tricyclic inhibitors of poly(ADP-ribose) polymerases |
| 04/24/2003 | US20030078252 Used to treat abnormal cell growth and central nervous system disorders |
| 04/24/2003 | US20030078246 Combinations for the treatment of inflammatory disorders |
| 04/24/2003 | US20030078244 Regulation of intracellular glucocorticoid concentrations |
| 04/24/2003 | US20030078241 Treating effects of excessive reactive oxygen species |
| 04/24/2003 | US20030078240 Reducing plaque formation, for the treatment of Alzheimer's disease |
| 04/24/2003 | US20030078239 Ketone compounds and compositions for cholesterol management and related uses |
| 04/24/2003 | US20030078236 Arylsulfanyl and heteroarylsulfanyl derivatives for treating pain |
| 04/24/2003 | US20030078235 Treatment of central nervous system disorders; anticonvulsants, antiepileptics, neuroprotective agents and muscle relaxants |
| 04/24/2003 | US20030078232 A stimulants for bone marrow cell proliferation, countering the toxic side effect of drugs, in particular chemotherapeutic drugs, such as leukopenia and neutropenia |
| 04/24/2003 | US20030078212 Pharmaceutical compositions containing poly(adp-ribose) glycohydrolase inhibitors and methods of using the same |
| 04/24/2003 | US20030078200 Treating a DSM-III disorder by administering to a mammal a peptide or a peptidomimetic thereof to reduce or eliminate symptoms of the DSM-III disorder |
| 04/24/2003 | US20030078166 Pyrazole compounds useful as protein kinase inhibitors |
| 04/24/2003 | US20030077826 Chimeric molecules containing a module able to target specific cells and a module regulating the apoptogenic function of the permeability transition pore complex (PTPC) |
| 04/24/2003 | US20030077823 Hair follicle stem cells for use in the treatment of nervous system disorders and cell therapy |
| 04/24/2003 | US20030077798 Nucleotide sequences coding polypeptide for use in the treatment of alzheimer's, diabetes and inflammation |
| 04/24/2003 | US20030077749 Ucp5 |
| 04/24/2003 | US20030077735 Novel human Kchannel and therapeutic applications thereof |
| 04/24/2003 | US20030077734 Isolated human G-protein coupled receptors, nucleic acid molecules encoding human GPCR proteins, and uses thereof |
| 04/24/2003 | US20030077665 Detection of nervous system modulators; obtain preferential nervous system tissue in vitro, culture, incubate with modulator, monitor and evaluate adjustment in cell activity |
| 04/24/2003 | US20030077638 MID 4460, a human tyrosine phosphatase family member and uses therefor |
| 04/24/2003 | US20030077624 Diagnosing cancer in mammals; obtain sample cells, monitor expression of collapsin protein, amplified concentration of collapsin indicates cancer |
| 04/24/2003 | US20030077585 Nucleotide sequences coding polypeptide for use in the diagnosis, detection, prevention and treatment of bacterial infection |
| 04/24/2003 | US20030077327 Highly compressible ethylcellulose for tableting |
| 04/24/2003 | US20030077313 Anti-stress composition intended for incorporation mainly in nutritional vehicles |
| 04/24/2003 | US20030077291 Active enamel matrix substance, such as an amelogenin, a processed amelogenin product, or a metabolite can be used in treating conditions in a mammal which present an imbalance in its native immune resposne to external or internal stimuli |
| 04/24/2003 | US20030077271 Use of coagulation factor VII-activating protease for the prophylaxis and therapy of vasoproliferative disorders |
| 04/24/2003 | US20030077258 Comprising one or more chondroitin sulfate proteoglycan (CSPG)-degrading enzymes that promote axonal penetration into damaged nerve tissue and nerve graft |
| 04/24/2003 | US20030077252 Vaccination against plaque forming diseases; inhibiting aggregation of amyloid in mammal and/or to cause disaggregation of amyloid; treating brain disorder, Alzheimer's disease |
| 04/24/2003 | US20030077249 DNA coding for one or more recombinant chimeric receptors comprising two or more different cytoplasmic signalling polypeptides; drug delivery system for treating cancer |
| 04/24/2003 | US20030077246 TNFr/OPG-like molecules and uses thereof |
| 04/24/2003 | US20030075172 Method and apparatus for dispensing inhalator medicament |
| 04/24/2003 | CA2727642A1 Synthesis of cyclosporin analogs |
| 04/24/2003 | CA2494706A1 Chimeric glycosylphosphatidylinositol containing peptides |
| 04/24/2003 | CA2464412A1 Tetracyclic azaindoles and -indolines having serotonin 5-ht2cactivity |
| 04/24/2003 | CA2463908A1 Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions |
| 04/24/2003 | CA2463850A1 Remodeling of tissues and organs |
| 04/24/2003 | CA2463729A1 Treatment of infectious disease using interleukin-1 beta converting enzyme (ice)/ced-3 family inhibitors |
| 04/24/2003 | CA2463724A1 Organosulfur inhibitors of tyrosine phosphatases |
| 04/24/2003 | CA2463686A1 Benzoxazine and benzothiazine derivatives and pharmaceutical compositions containing them |
| 04/24/2003 | CA2463685A1 Novel .beta.-phenyl-.alpha.-oxysubstituted propionic derivatives: process for its preparation and their use in the preparation of pharmaceutically important compounds |
| 04/24/2003 | CA2463676A1 Compositions and methods for treating cellular response to injury and other proliferating cell disorders regulated by hyaladherin and hyaluronans |
| 04/24/2003 | CA2463624A1 Anti-glycation agents for preventing age-, diabetes-, and smoking-related complications |
| 04/24/2003 | CA2463597A1 Rosuvastatin in pre demented states |
| 04/24/2003 | CA2463579A1 Treatment of cns disorders using cns target modulators |
| 04/24/2003 | CA2463518A1 Carbinols for the treatment of neuropathic dysfunction |
| 04/24/2003 | CA2463509A1 Lactam derivatives as antagonists for human 11cby receptors |
| 04/24/2003 | CA2463508A1 Pyrimidinones as melanin concentrating hormone receptor 1 |
| 04/24/2003 | CA2463469A1 4-(4-alkoxy-3-hydroxyphenyl)-2-pyrrolidone derivatives as pde-4 inhibitors for the treatment of neurological syndromes |
| 04/24/2003 | CA2463426A1 Substituted piperazine cyclohexane carboxilic acid amides and the use thereof |
| 04/24/2003 | CA2463020A1 Use of gp130 activators in diabetic neuropathy |
| 04/24/2003 | CA2463016A1 Composition comprising paracetamol and a bitterness masking component |
| 04/24/2003 | CA2462980A1 Quinuclidine derivatives, processes for preparing them and their uses as m2 and/or m3 muscarinic receptor inhibitors |
| 04/24/2003 | CA2462785A1 Kinases and phosphatases |
| 04/24/2003 | CA2462441A1 1,4-disubstituted benzo-fused urea compounds as cytokine inhibitors |
| 04/24/2003 | CA2462147A1 Bicyclic oxopyridine and oxopyrimidine derivatives |
| 04/24/2003 | CA2461542A1 Gap junctions and endothelial-derived hyperpolarizing factor (edhf) |
| 04/24/2003 | CA2461245A1 Protein based tnf-alpha variants for the treatment of tnf-alpha related disorders |
| 04/24/2003 | CA2461170A1 Peptidyl ketones as inhibitors of dpiv |
| 04/24/2003 | CA2460685A1 Cyclosporine analogue mixtures and their use as immunomodulating agents |
| 04/23/2003 | EP1304324A1 Serotonin reuptake inhibitors |
| 04/23/2003 | EP1304119A2 Method for preventing and treating hearing loss using a neurturin protein product |
| 04/23/2003 | EP1304101A1 Composition and method for use of pyridinium derivatives in cosmetic and therapeutic applications |
| 04/23/2003 | EP1303625A2 Alpha-msh related compounds and methods of use |
| 04/23/2003 | EP1303620A2 Regulation of human desc1-like serine protease |
| 04/23/2003 | EP1303619A1 A novel human soluble secreted endopeptidase (sep) for the treatment of sexual dysunfction |
| 04/23/2003 | EP1303607A2 High affinity soluble interleukin-18 receptor |
| 04/23/2003 | EP1303603A2 G protein-coupled receptor con-218 |
| 04/23/2003 | EP1303601A2 G protein-coupled receptors |
| 04/23/2003 | EP1303600A2 Cell-permeable peptide inhibitors of the jnk signal transduction pathway |
| 04/23/2003 | EP1303596A2 Antisense enzyme inhibitors for improving pharmacokinetics of a drug |
| 04/23/2003 | EP1303537A2 Ho-1 suppressor as a diagnostic and prognostic test for dementing diseases |
| 04/23/2003 | EP1303528A1 Adenosine compound and pharmaceutical composition containing the same |
| 04/23/2003 | EP1303527A1 Matrix metalloproteinase inhibitors |
| 04/23/2003 | EP1303522A2 Biologically active macrolides, compositions, and uses thereof |
| 04/23/2003 | EP1303521A1 Tetrahydro-heterocycloazepinyl pyrimidine derivatives |
| 04/23/2003 | EP1303518A1 Imidazolophthalazine derivatives as ligands for gabaa receptors |
| 04/23/2003 | EP1303517A1 Indoloquinazolinones |
| 04/23/2003 | EP1303516A1 Imidazolophthalazine derivatives as ligands for gaba a? receptors |
| 04/23/2003 | EP1303512A1 Process for preparing arylacetylaminothiazoles |
| 04/23/2003 | EP1303507A1 Pyrimidine derivatives |
| 04/23/2003 | EP1303506A1 6-heteroarylphenanthridines |
| 04/23/2003 | EP1303502A2 Tetrahydrobenzothiazole analogues as neuroprotective agents |
| 04/23/2003 | EP1303501A1 Cyanomethyl substituted thiazoliums and imidazoliums and treatments of disorders associated with protein aging |
| 04/23/2003 | EP1303499A1 Tetrazole derivatives |
| 04/23/2003 | EP1303495A1 Substituted 5-alkynyl pyrimidines having neurotrophic activity |
| 04/23/2003 | EP1303492A2 Aza-bridged-bicyclic amino acid derivatives as alpha 4 integrin antagonists |
| 04/23/2003 | EP1303490A1 N-oxides as nk1 receptor antagonist prodrugs of 4-phenyl-pyridine derivatives |
| 04/23/2003 | EP1303486A1 Pyrrolidine derivatives as metalloprotease inhibitors |
| 04/23/2003 | EP1303485A1 Pyrrolidine derivatives as inhibitors of endothelin-converting enzyme |
| 04/23/2003 | EP1303483A1 Novel thiourea derivatives and the pharmaceutical compositions containing the same |
| 04/23/2003 | EP1303477A2 1-amino-alkylcyclohexanes as 5-ht3- and neuronal nicotinicreceptor antagonists |
| 04/23/2003 | EP1303304A2 Pharmaceutical combinations for treatment and prevention of diabetes mellitus |
| 04/23/2003 | EP1303302A2 Use of strains of the parapox ovis virus against organ fibrosis |
| 04/23/2003 | EP1303289A2 Use of derivatives of valproic acid and 2-valproenic acid amides for the treatment of mania in bipolar disorder |
| 04/23/2003 | EP1303286A2 Use of strains of the parapox ovis virus for producing antiviral pharmaceuticals and anticancer pharmaceuticals |
| 04/23/2003 | EP1303279A1 Method of treating peripheral vascular diseases, peripheral neuropathies, and autonomic neuropathies |
| 04/23/2003 | EP1303278A1 Combination of a transdermal therapeutic system and an oral and/or parenteral preparation containing dopamine agonists for the treatment of dopaminergic disease states |
| 04/23/2003 | EP1303277A1 Pharmaceutical composition based on cocaethylene and use thereof for treating psychoactive substance dependence |